135 related articles for article (PubMed ID: 10462256)
1. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.
Macdougall IC
Nephrol Dial Transplant; 1999 Aug; 14(8):1836-41. PubMed ID: 10462256
[No Abstract] [Full Text] [Related]
2. Ace inhibitors and erythropoietin response in hemodialysis patients.
Ertürk S
Am J Kidney Dis; 2000 Oct; 36(4):880. PubMed ID: 11007696
[No Abstract] [Full Text] [Related]
3. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients.
Naito M; Kawashima A; Akiba T; Takanashi M; Nihei H
Am J Nephrol; 2003; 23(5):287-93. PubMed ID: 12897465
[TBL] [Abstract][Full Text] [Related]
4. Effects of Epoetin alfa on hemostasis in chronic renal failure.
Tang WW; Stead RA; Goodkin DA
Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
Bieber E
J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietic recovery during treatment with darbepoietin-alpha after impaired rHuEPO response to anemia in two patients with osteomyelofibrosis after peripheral blood stem cell transplantation.
Nguyen VA; Fauser AA; Basara N; Kiehl M
Hematol J; 2003; 4(6):456-8. PubMed ID: 14671623
[No Abstract] [Full Text] [Related]
7. Erythropoiesis-stimulating agents: development, detection and dangers.
Franz SE
Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
9. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
Adamson JW; Ludwig H
Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis stimulating agents: a personal journey.
Leyland-Jones B
J Natl Cancer Inst; 2013 Jul; 105(14):999-1001. PubMed ID: 23860202
[No Abstract] [Full Text] [Related]
11. Epoetin alfa: to give or not to give.
Dang C; Hudis C; Norton L
J Natl Cancer Inst; 2013 Jul; 105(14):1001-3. PubMed ID: 23860203
[No Abstract] [Full Text] [Related]
12. [Epoetin alfa: recent strategies of use].
Tumori; 1997; 83(6):975-8. PubMed ID: 9537918
[No Abstract] [Full Text] [Related]
13. Focus on epoetin: key findings of mini-sessions.
Semin Oncol; 1998 Jun; 25(3 Suppl 7):69-75. PubMed ID: 9671335
[No Abstract] [Full Text] [Related]
14. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
[No Abstract] [Full Text] [Related]
15. Oral ascorbic acid as adjuvant to epoetin alfa in hemodialysis patients with hyperferritinemia.
Nguyen TV
Am J Health Syst Pharm; 2004 Oct; 61(19):2007-8. PubMed ID: 15509119
[No Abstract] [Full Text] [Related]
16. Use of epoetin in chronic renal failure.
Coyne DW
JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
[No Abstract] [Full Text] [Related]
17. Epoetin dosing and dialysis facility ownership.
Kliger AS; Nissenson AR
JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
[No Abstract] [Full Text] [Related]
18. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
[TBL] [Abstract][Full Text] [Related]
19. [Should erythropoietin be administered to old patients in the preoperative period of orthopaedics surgery?].
Páramo Fernández JA
Med Clin (Barc); 2004 Oct; 123(11):421-2. PubMed ID: 15482717
[No Abstract] [Full Text] [Related]
20. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Ogawa T; Nitta K
Contrib Nephrol; 2015; 185():76-86. PubMed ID: 26023017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
